IP Library Granted Patent US 11,678,800
Granted Patent B2
US 11,678,800 · App. 16/520,936 · Granted Jun 20, 2023

Subcutaneous outpatient management

Inventors: Robert C. Booth (Columbus, NC); Harry Hebblewhite (Atlanta, GA)
Assignee: Aseko, Inc.
A61B5/0022A61B5/14503A61B5/14532A61B5/4839A61M5/1723G16H10/40G16H10/60G16H20/17G16H20/60G16H40/67G16H50/20G16Z99/00A61M2205/3303
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,678,800
App. No.
16/520,936
Granted
Jun 20, 2023
Kind
B2
Abstract

A method of administering insulin includes receiving subcutaneous information for a patient at a computing device and executing a subcutaneous outpatient program for determining recommended insulin dosages. The subcutaneous outpatient program includes obtaining blood glucose data of the patient from a glucometer in communication with the computing device, aggregating blood glucose measurements to determine a representative aggregate blood glucose measurement associated with at least one scheduled blood glucose time interval, and determining a next recommended insulin dosage for the patient based on the representative aggregate blood glucose measurement and the subcutaneous information. The method also includes transmitting the next recommended insulin dosage to a portable device associated with the patient. The portable device displays the next recommended insulin dosage.

Claims (52)

1. A method comprising:

receiving, at data processing hardware of a patient device, glucose data of a patient associated with the patient device, the glucose data including glucose measurements of the patient and glucose times associated with the glucose measurements;

transmitting, by the data processing hardware, the glucose data to a remote server, the remote server executing a subcutaneous outpatient process configured to:

receive sequential scheduled glucose time intervals throughout a day, each scheduled glucose time interval associated with a corresponding adjustable time boundary that does not overlap with other time boundaries associated with the other scheduled glucose time intervals;

for each scheduled glucose time interval, aggregate the glucose measurements of the glucose data received from the patient device that are associated with the corresponding scheduled glucose time interval based on the glucose times to determine a corresponding representative aggregate glucose measurement associated with the corresponding scheduled glucose time interval; and

determine a next recommended carbohydrate-to-insulin ratio for the patient during a selected time interval based on the representative aggregate glucose measurement associated with the scheduled glucose time interval that occurs immediately after the selected time interval;

receiving, at the data processing hardware, the next recommended carbohydrate-to-insulin ratio for the patient during the selected time interval from the remote server;

executing, by the data processing hardware, an insulin management program configured to display on a display of the patient device in communication with the data processing hardware a graphical user interface having a carbohydrate input field, wherein the insulin management program is configured to:

receive, at the carbohydrate input field, a total number of carbohydrates consumed by the patient during the selected time interval;

determine, based on the number of carbohydrates consumed by the patient and the next recommended carbohydrate-to-insulin ratio for the patient during the selected time interval, a recommended meal bolus for the patient to administer during the selected time interval; and

display, during the selected time interval, the recommended meal bolus on the display of the patient device; and

transmitting the recommended meal bolus from the data processing hardware to an administration device in communication with the data processing hardware, the administration device configured to automatically dial in a number of units of insulin for the recommended meal bolus and administer the number of units of insulin for the recommended meal bolus.

2. The method of claim 1 , wherein the subcutaneous outpatient process is configured to receive the sequential scheduled glucose time intervals throughout the day from a healthcare provider computing device in communication with the remote server.

3. The method of claim 1 , further comprising displaying, by the data processing hardware, the number of carbohydrates consumed by the patient during the selected time interval on the display of the patient device.

4. The method of claim 1 , wherein receiving the glucose data comprises receiving the glucose data from a remote computing device in communication with the data processing hardware during a batch download process, the remote computing device executing a download program for downloading the glucose data from a glucometer or a continuous glucose monitoring system associated with the patient.

5. The method of claim 1 , wherein the administration device comprises a smart insulin pen.

6. The method of claim 1 , wherein the administration device comprises an insulin pump.

7. The method of claim 1 , wherein the subcutaneous outpatient process is further configured to:

aggregate one or more of the glucose measurements associated with a selected one of the scheduled glucose time intervals to determine a representative aggregate glucose measurement associated with the selected scheduled glucose time interval;

select a governing glucose as the representative aggregate glucose measurement associated with the selected scheduled glucose time interval;

determine an adjustment factor for adjusting a next recommended meal bolus governed by the selected scheduled glucose time interval based on the selected governing glucose measurement;

obtain a previous day recommended meal bolus governed by the selected scheduled glucose time interval; and

determine the next recommended meal bolus by multiplying the adjustment factor times the previous day recommended meal bolus.

8. The method of claim 1 , wherein the representative aggregate glucose measurement includes one of:

a mean glucose value for the associated scheduled glucose time interval; or

a median glucose value for the associated scheduled glucose time interval.

9. A patient device comprising:

data processing hardware; and

memory hardware in communication with the data processing hardware, the memory hardware storing instructions that when executed on the data processing hardware cause the data processing hardware to perform operations comprising:

receiving glucose data of a patient associated with the patient device, the glucose data including glucose measurements of the patient and glucose times associated with the glucose measurements;

transmitting the glucose data to a remote server, the remote server executing a subcutaneous outpatient process configured to:

receive sequential scheduled glucose time intervals throughout a day, each scheduled glucose time interval associated with a corresponding adjustable time boundary that does not overlap with other time boundaries associated with the other scheduled glucose time intervals;

for each scheduled glucose time interval, aggregate the glucose measurements of the glucose data received from the patient device that are associated with the corresponding scheduled glucose time interval based on the glucose times to determine a corresponding representative aggregate glucose measurement associated with the corresponding scheduled glucose time interval; and

determine a next recommended carbohydrate-to-insulin ratio for the patient during a selected time interval based on the representative aggregate glucose measurement associated with the scheduled glucose time interval that occurs immediately after the selected time interval;

receiving the next recommended carbohydrate-to-insulin ratio for the patient during the selected time interval from the remote server;

executing an insulin management program configured to display on a display of the patient device in communication with the data processing hardware a graphical user interface having a carbohydrate input field, wherein the insulin management program is configured to:

receive, at the carbohydrate input field, a total number of carbohydrates consumed by the patient during the selected time interval;

determine, based on the number of carbohydrates consumed by the patient and the next recommended carbohydrate-to-insulin ratio for the patient during the selected time interval, a recommended meal bolus for the patient to administer during the selected time interval; and

display, during the selected time interval, the recommended meal bolus on the display of the patient device; and

transmitting the recommended meal bolus from the data processing hardware to an administration device in communication with the data processing hardware, the administration device configured to automatically dial in a number of units of insulin for the recommended meal bolus and administer the number of units of insulin for the recommended meal bolus.

10. The patient device of claim 9 , wherein the subcutaneous outpatient process is configured to receive the sequential scheduled glucose time intervals throughout the day from a healthcare provider computing device in communication with the remote server.

11. The patient device of claim 9 , wherein the operations further comprise displaying the number of carbohydrates consumed by the patient during the selected time interval on the display of the patient device.

12. The patient device of claim 9 , wherein receiving the glucose data comprises receiving the glucose data from a remote computing device in communication with the data processing hardware during a batch download process, the remote computing device executing a download program for downloading the glucose data from a glucometer or a continuous glucose monitoring system associated with the patient.

13. The patient device of claim 9 , wherein the administration device comprises a smart insulin pen.

14. The patient device of claim 9 , wherein the subcutaneous outpatient process is further configured to:

aggregate one or more of the glucose measurements associated with a selected one of the scheduled glucose time intervals to determine a representative aggregate glucose measurement associated with the selected scheduled glucose time interval;

select a governing glucose as the representative aggregate glucose measurement associated with the selected scheduled glucose time interval;

determine an adjustment factor for adjusting a next recommended meal bolus governed by the selected scheduled glucose time interval based on the selected governing glucose measurement;

obtain a previous day recommended meal bolus governed by the selected scheduled glucose time interval; and

determine the next recommended meal bolus by multiplying the adjustment factor times the previous day recommended meal bolus.

15. The patient device of claim 9 , wherein the representative aggregate glucose measurement includes one of:

a mean glucose value for the associated scheduled glucose time interval; or a median glucose value for the associated scheduled glucose time interval.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 2, 2024
From: ASEKO, INC.
To: GLYTEC, LLC
Reel/Frame 067320/0764 →
SECURITY INTEREST Recorded Aug 8, 2023
From: ASEKO, INC.
To: HAYFIN SERVICES LLP, AS THE AGENT
Reel/Frame 064517/0872 →
RELEASE OF SECURITY INTEREST Recorded Aug 8, 2023
From: NEWLIGHT CAPITAL LLC
To: ASEKO, INC.; GLYTEC, LLC
Reel/Frame 064530/0362 →
SECURITY INTEREST Recorded Jun 6, 2022
From: ASEKO, INC.; GLYTEC, LLC
To: NEWLIGHT CAPITAL LLC, AS SERVICER
Reel/Frame 060283/0849 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 20, 2019
From: BOOTH, ROBERT C.; HEBBLEWHITE, HARRY
To: ASEKO, INC.
Reel/Frame 051062/0952 →
Continuity (5)
Continuation 16124026 · Sep 6, 2018
Continuation 15855315 · Dec 27, 2017
Continuation 14922763 · Oct 26, 2015
Provisional Application 62069195 · Oct 27, 2014
Related Publication 20190348166A1 · Nov 14, 2019